What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen's obesity drug cuts weight by up to 20%, trial data drags down shares
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
Amgen's obesity drug causes up to 20% weight loss, trial data weighs on shares
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of people who ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
BioPharma Dive7h
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen stock slips as obesity drug study disappoints Wall Street
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...
FierceBiotech10h
Amgen’s monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen falls after obesity study results
Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 12% Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).
Amgen Says Its Weight Loss Drug Candidate MariTide Reduced Weight Up To 20 Percent In Phase 2 Study
Tuesday reported encouraging results from its Phase 2 study of MariTide in people with obesity. Results from the 2 ...